  |
Lægemiddelstofklassifikation ATC |
M | ||
  |
Antineoplastiske og immunomodulerende midler |
ML | ||
   |
immunsuppressiva |
ML04 | ||
 |
immunsuppressiva |
ML04A | ||
|
interleukinhæmmere |
ML04AC | ||
 |
daclizumab |
ML04AC01 | ||
 |
basiliximab |
ML04AC02 | ||
 |
anakinra |
ML04AC03 | ||
 |
rilonacept |
ML04AC04 | ||
 |
ustekinumab |
ML04AC05 | ||
 |
tocilizumab |
ML04AC07 | ||
 |
canakinumab |
ML04AC08 | ||
 |
briakinumab |
ML04AC09 | ||
 |
secukinumab |
ML04AC10 | ||
 |
siltuximab |
ML04AC11 | ||
 |
brodalumab |
ML04AC12 | ||
 |
ixekizumab |
ML04AC13 | ||
 |
sarilumab |
ML04AC14 | ||
 |
sirukumab |
ML04AC15 | ||
 |
guselkumab |
ML04AC16 | ||
 |
tildrakizumab |
ML04AC17 | ||
 |
risankizumab |
ML04AC18 | ||
 |
satralizumab |
ML04AC19 | ||
 |
netakimab |
ML04AC20 | ||
 |
bimekizumab |
ML04AC21 | ||
 |
spesolimab |
ML04AC22 | ||
 |
olokizumab |
ML04AC23 | ||
 |
mirikizumab |
ML04AC24 | ||
 |
levilimab |
ML04AC25 | ||
 |
goflikicept |
ML04AC26 |
TEXT